The U.S. Food and Drug Administration has approved the new drug application NDA018090 for a sodium chloride injection.
The product is marketed as Sodium Chloride 0.45% in a plastic container and is administered intravenously. It is an injectable solution containing 450 mg of sodium chloride per 100 mL and is classified as a prescription human drug.
ICU Medical Inc. is listed as the manufacturer. The approval references multiple package NDC codes (e.g., 0990-7730-36, 0990-7983-61) and a series of FDA submissions covering manufacturing (CMC) and labeling from 1980 through 1998.
This approval expands the portfolio of FDA‑cleared intravenous fluids available for clinical use.
Regulatory UpdatesSep 9, 2026•1 min read
FDA Approves Sodium Chloride Injection (NDA018090)
The FDA has approved NDA018090 for Sodium Chloride 0.45% injectable, manufactured by ICU Medical Inc.
Compiled by the PharmaCountry team · Source: FDA.gov
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating